← All trials
NCT05940220
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Oct 10, 2025
- First posted
- Jul 11, 2023
- Last posted
- Aug 1, 2023
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TehranLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.